RxDoctor Payments Data

James Fry

Neurology with Special Qualifications in Child Neurology · Nashville, TNNPI 1659482305

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $50,150 of the $79,899 with a category attached, or 62.8%. Supernus Pharmaceuticals, Inc. accounts for 65.0% of it on its own, with 39 other manufacturers making up the rest. Reporting peaked in 2021 at $39,782 and has fallen 94.6% since, to $2,137 in 2025.

$79,899in general payments, 2019–2025

Across 972 payments — averaging $82.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Supernus Pharmaceuticals, Inc.$52K
  • Ironshore Pharmaceuticals Inc.$13K
  • SK Life Science, Inc.$3K
  • Neurocrine Biosciences, Inc.$2K
  • Neurelis, Inc.$1K
  • Aquestive Therapeutics, Inc.$981
  • plus $7K from 34 others
$2,444,074in research payments, 2019–2025

Across 625 payments — averaging $3910.52 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$1.8M
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$268K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$216K
  • Biohaven Pharmaceutical Holding Company Ltd.$65K
  • Eli Lilly$45K
  • Biohaven Pharmaceuticals, Inc.$26K
  • plus $21K from 1 others

What the payments were for

  • Speaking & faculty fees$50,15063%
  • Travel & lodging$10,50513%
  • Food & beverage$19,21824%
  • Education$250%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$79,899 in reported general payments places this provider in the 85th percentile of 47 neurology with special qualifications in child neurology providers in Tennessee.

See all neurology with special qualifications in child neurology providers in Tennessee

Most prescribed under Part D

DrugClaimsCost to plans & patients
SabrilVigabatrin23$871,383
AfinitorEverolimus11$216,236
XcopriCenobamate41$79,466
EpidiolexCannabidiol (Cbd)13$59,549
TrileptalOxcarbazepine36$50,758
SympazanClobazam11$42,019
Oxcarbazepine47$3,895
Lacosamide19$1,636
Zonisamide35$1,613
CarbatrolCarbamazepine11$1,094
Methylphenidate ErMethylphenidate Hcl11$1,069
Lamotrigine35$918
Risperidone34$638
Levetiracetam20$557
Topiramate18$232

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisAfinitor$15$216,23611 claims
SK Life Science, Inc.Xcopri$3,262$79,46641 claims
Aquestive Therapeutics, Inc.Sympazan$981$42,01911 claims
Upsher-smith Laboratories LLCTopiramate$55$23218 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 47 neurology with special qualifications in child neurology providers in Tennessee.

Other neurology with special qualifications in child neurology in Nashville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →